Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial

  • Birgitte Krogsgaard Andersen
  • , Martin Sejr-Hansen
  • , Jelmer Westra
  • , Gianluca Campo
  • , Ashkan Efterkhari
  • , Shengxian Tu
  • , Javier Escaned
  • , Lukasz Koltowski
  • , Barbara Stähli
  • , Andrejs Erglis
  • , Gediminas Jaruševičius
  • , Greta Žiubrytė
  • , Truls Råmunddal
  • , Tommy Liu
  • , William Wijns
  • , Ulf Landmesser
  • , Luc Maillard
  • , Hitoshi Matsuo
  • , Evald Høj Christiansen
  • , Niels Ramsing Holm*
  • *Šī darba korespondējošais autors
  • Aarhus University
  • University of Ferrara
  • Maria Cecilia Hospital
  • Aalborg University
  • Shanghai Jiao Tong University
  • Complutense University
  • Medical University of Warsaw
  • University of Zurich
  • Riga Stradins University
  • Lithuanian University of Health Sciences
  • Sahlgrenska University Hospital
  • Haga Ziekenhuis
  • University of Galway
  • Charité – Universitätsmedizin Berlin
  • Clinique Axium
  • Gifu Heart Center

Zinātniskās darbības rezultāts: Devums žurnālamZinātniskais raksts (žurnālā)koleģiāli recenzēts

30 Atsauces (Scopus)

Kopsavilkums

Quantitative flow ratio (QFR) is a computation of fractional flow reserve (FFR) based on invasive coronary angiographic images. Calculating QFR is less invasive than measuring FFR and may be associated with lower costs. Current evidence supports the call for an adequately powered randomised comparison of QFR and FFR for the evaluation of intermediate coronary stenosis. The aim of the FAVOR III Europe Japan trial is to investigate if a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with a standard FFR-guided strategy in the evaluation of patients with intermediary coronary stenosis. FAVOR III Europe Japan is an investigator-initiated, randomised, clinical outcome, non-inferiority trial scheduled to randomise 2,000 patients with either 1) stable angina pectoris and intermediate coronary stenosis, or 2) indications for functional assessment of at least 1 non-culprit lesion after acute myocardial infarction. Up to 40 international centres will randomise patients to either a QFR-based or a standard FFR-based diagnostic strategy. The primary endpoint of major adverse cardiovascular events is a composite of all-cause mortality, any myocardial infarction, and any unplanned coronary revascularisation at 12 months. QFR could emerge as an adenosine- and wire-free alternative to FFR, making the functional evaluation of intermediary coronary stenosis less invasive and more cost-effective.

OriģinālvalodaAngļu
Lapas (no-līdz)E1357-E1364
ŽurnālsEuroIntervention
Sējums18
Izdevuma numurs16
DOIs
Publikācijas statussPublicēts - apr. 2023
Ārēji publicēts

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial”. Kopā tie veido unikālu nospiedumu.

Citēt šo